MF59-adjuvanted quadrivalent influenza vaccine

The MF59-adjuvanted quadrivalent influenza vaccine is an inactivated influenza vaccine containing four viral strains (two influenza A and two influenza B) and the MF59 adjuvant, an oil-in-water emulsion of squalene. MF59 enhances the immune response by creating a transient immunocompetent environment at the injection site, recruiting key immune cells, increasing antigen uptake, and promoting more efficient adaptive immune activation, including CD4+ T-cell and B-cell responses. The vaccine is designed for improved immunogenicity and effectiveness, particularly in children and older adults, compared to non-adjuvanted vaccines. Developed and manufactured primarily by Seqirus, it is approved for individuals ≥65 years (Fluad Quadrivalent) and has pending/approved pediatric formulations.

Brand names

Fluad Quadrivalent PediatricFluad Quadrivalent

Other names

aQIVMF59-adjuvanted QIVMF-59-adjuvanted QIVMF 59-adjuvanted QIV